AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18984662 — intervention group
Group type: COMPARATOR
Intervention: 240 mg/d oral iron alone
Number of subjects: 51
Study 18984662 — intervention group
Group type: EXPERIMENTAL
Intervention: 240 mg/d oral iron plus 75 microg/d levothyroxine
Number of subjects: 51
Study 16893507 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin drip
Number of subjects: 36
Study 16893507 — intervention group
Group type: COMPARATOR
Intervention: Rotating fluids
Number of subjects: 36
Study 15536773 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief intervention with feedback on CDT levels
Number of subjects: 151
Study 15536773 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 151
Study 11419846 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening group (flexible sigmoidoscopy)
Number of subjects: 799
Study 11419846 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 799
Study 9285419 — intervention group
Group type: EXPERIMENTAL
Intervention: MRA (Magnetic Resonance Angiography)
Number of subjects: 14
Study 9285419 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI (Magnetic Resonance Imaging)
Number of subjects: 14
Study 9285419 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-D TOF MRA
Number of subjects: 14
Study 9285419 — intervention group
Group type: EXPERIMENTAL
Intervention: Spin-echo sequences
Number of subjects: 14
Study 9285419 — intervention group
Group type: COMPARATOR
Intervention: Catheter angiography
Number of subjects: 14
Study 8313865 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin (500 mg bid)
Number of subjects: 497
Study 8313865 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate (500 mg tid)
Number of subjects: 497
Study 3091629 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH pulses (1 microgram/kg, iv) at 2-h intervals during day (0900-2100 h) and night (2100-0900 h)
Number of subjects: 15
Study 3091629 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous GHRH infusion (0.15 microgram/kg X h for 5 h, followed by 0.75 microgram/kg X h for 5 h)
Number of subjects: 15
Study 3091629 — intervention group
Group type: COMPARATOR
Intervention: Single GHRH bolus dose (1 microgram/kg, iv) after continuous GHRH infusion
Number of subjects: 15
Study 3091629 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 15
Study 31470942 — intervention group
Group type: EXPERIMENTAL
Intervention: Back-flow hydrodissection
Number of subjects: 200
Study 31470942 — intervention group
Group type: COMPARATOR
Intervention: Conventional hydrodissection
Number of subjects: 200
Study 29557398 — intervention group
Group type: EXPERIMENTAL
Intervention: Zygomatic implants
Number of subjects: 71
Study 29557398 — intervention group
Group type: COMPARATOR
Intervention: Augmentation procedures
Number of subjects: 71
Study 26463556 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin drops
Number of subjects: 149
Study 26463556 — intervention group
Group type: COMPARATOR
Intervention: Conservative observation
Number of subjects: 149
Study 25935963 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg mifepristone
Number of subjects: 80
Study 25935963 — intervention group
Group type: COMPARATOR
Intervention: 200 mg mifepristone
Number of subjects: 80
Study 21891773 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra high-volume hemofiltration (EHVHF) at 85 mL/kg/h
Number of subjects: 280
Study 21891773 — intervention group
Group type: COMPARATOR
Intervention: High-volume hemofiltration (HVHF) at 50 mL/kg/h
Number of subjects: 280
Study 21891773 — intervention group
Group type: EXPERIMENTAL
Intervention: EHVHF and HVHF
Number of subjects: 280
Study 20358276 — intervention group
Group type: COMPARATOR
Intervention: Day 3 morphology score (Group A)
Number of subjects: 214
Study 20358276 — intervention group
Group type: EXPERIMENTAL
Intervention: GES-scoring plus sHLA-G expression (Group B)
Number of subjects: 214
Study 17974605 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial contrast injection (IACTA)
Number of subjects: 32
Study 17974605 — intervention group
Group type: COMPARATOR
Intervention: Conventional CT angiography with intravenous contrast injection (IVCTA)
Number of subjects: 32
Study 17974605 — intervention group
Group type: EXPERIMENTAL
Intervention: IACTA
Number of subjects: 32
Study 17974605 — intervention group
Group type: COMPARATOR
Intervention: IVCTA
Number of subjects: 32
Study 16026728 — intervention group
Group type: EXPERIMENTAL
Intervention: Original Focus on Kids (OFOK)
Number of subjects: 999
Study 16026728 — intervention group
Group type: EXPERIMENTAL
Intervention: West Virginia Focus on Kids (WVFOK)
Number of subjects: 999
Study 16026728 — intervention group
Group type: COMPARATOR
Intervention: Control condition (training in environmental conservation)
Number of subjects: 999
Study 11859910 — intervention group
Group type: EXPERIMENTAL
Intervention: Almotriptan
Number of subjects: 0
Study 11859910 — intervention group
Group type: COMPARATOR
Intervention: Sumatriptan
Number of subjects: 0
Study 10612135 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopically assisted bone‐tendon‐bone A.C.L. reconstruction
Number of subjects: 64
Study 10612135 — intervention group
Group type: COMPARATOR
Intervention: Open procedure A.C.L. reconstruction
Number of subjects: 64
Study 8561671 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 16
Study 8561671 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 2024559 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine
Number of subjects: 30
Study 2024559 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine with epinephrine (5 micrograms.ml‐1)
Number of subjects: 30
Study 2024559 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 30
Study 7044206 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 0
Study 7044206 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31717739 — intervention group
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training (HIIT)
Number of subjects: 56
Study 31717739 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 56
Study 28891388 — intervention group
Group type: EXPERIMENTAL
Intervention: High social-evaluative body image threat condition
Number of subjects: 66
Study 28891388 — intervention group
Group type: COMPARATOR
Intervention: Low social-evaluative body image threat condition
Number of subjects: 66
Study 26581915 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 57
Study 26581915 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 23754514 — intervention group
Group type: EXPERIMENTAL
Intervention: Darexaban-MR 120 mg qd + digoxin 0.25 mg qd
Number of subjects: 24
Study 23754514 — intervention group
Group type: COMPARATOR
Intervention: Placebo + digoxin 0.25 mg qd
Number of subjects: 24
Study 22960201 — intervention group
Group type: EXPERIMENTAL
Intervention: Spanish-English bilinguals
Number of subjects: 0
Study 22960201 — intervention group
Group type: COMPARATOR
Intervention: Control native speakers of English
Number of subjects: 0
Study 19574992 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.2 mg/kg premedication
Number of subjects: 179
Study 19574992 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 179
Study 19574992 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Midazolam and Control)
Number of subjects: 179
Study 17301626 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision support tool training for GPs (4-hour interactive session)
Number of subjects: 490
Study 17301626 — intervention group
Group type: COMPARATOR
Intervention: Educational materials about guidelines (control group)
Number of subjects: 490
Study 15965284 — intervention group
Group type: EXPERIMENTAL
Intervention: zoledronic acid
Number of subjects: 40
Study 15965284 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 40
Study 12172464 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous recombinant tissue plasminogen activator (rt-PA)
Number of subjects: 5000
Study 12172464 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5000
Study 10743479 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 micrograms folic acid each day
Number of subjects: 144
Study 10743479 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablet each day
Number of subjects: 144
Study 10743479 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 micrograms folic acid and placebo tablets on alternate days
Number of subjects: 144
Study 7723371 — intervention group
Group type: EXPERIMENTAL
Intervention: LPD (epirubicin 15-40 mg/m2 and Lipiodol 0.02-0.25 ml/kg)
Number of subjects: 43
Study 2386364 — intervention group
Group type: COMPARATOR
Intervention: Intravenous cefetamet
Number of subjects: 24
Study 2386364 — intervention group
Group type: COMPARATOR
Intervention: Oral cefetamet pivoxil
Number of subjects: 24
Study 7150459 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (300 mg every 6 h for 4 days)
Number of subjects: 0
Study 7150459 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31221934 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal Shockwave Therapy (ESWT)
Number of subjects: 72
Study 31221934 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 72
Study 30594217 — intervention group
Group type: EXPERIMENTAL
Intervention: Disposable sanitary pads distribution
Number of subjects: 3489
Study 30594217 — intervention group
Group type: EXPERIMENTAL
Intervention: Reproductive health education
Number of subjects: 3489
Study 30594217 — intervention group
Group type: EXPERIMENTAL
Intervention: Sanitary pad distribution and reproductive health education
Number of subjects: 3489
Study 30594217 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 3489
Study 27103467 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracentesis and indwelling catheter drainage
Number of subjects: 78
Study 24947926 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus vismodegib (VIS)
Number of subjects: 0
Study 24947926 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 0
Study 24947926 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoothened (Smo) shRNA or vismodegib (VIS)
Number of subjects: 0
Study 24947926 — intervention group
Group type: EXPERIMENTAL
Intervention: HH inhibition
Number of subjects: 0
Study 22890878 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone interview
Number of subjects: 1595
Study 22890878 — intervention group
Group type: COMPARATOR
Intervention: Questionnaire by mail
Number of subjects: 1595
Study 22890878 — intervention group
Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 1595
Study 19717243 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Family Counseling (BFC) plus Individual-Based Treatment (IBT)
Number of subjects: 29
Study 19717243 — intervention group
Group type: COMPARATOR
Intervention: Individual-Based Treatment (IBT) alone
Number of subjects: 29
Study 18779447 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated balloon
Number of subjects: 87
Study 18779447 — intervention group
Group type: COMPARATOR
Intervention: Control (uncoated balloon)
Number of subjects: 87
Study 16433710 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaglinide
Number of subjects: 15
Study 16433710 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide
Number of subjects: 15
Study 16433710 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (non-diabetic)
Number of subjects: 15
Study 14633758 — intervention group
Group type: COMPARATOR
Intervention: 30% oxygen
Number of subjects: 150
Study 14633758 — intervention group
Group type: COMPARATOR
Intervention: 80% oxygen
Number of subjects: 150
Study 14633758 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% oxygen with droperidol 0.625 mg
Number of subjects: 150
Study 10954389 — intervention group
Group type: EXPERIMENTAL
Intervention: Gatehouse Project intervention promoting healthy attachments, positive social climate, and curriculum-based health education.
Number of subjects: 0
Study 10954389 — intervention group
Group type: EXPERIMENTAL
Intervention: Curriculum-based health education integrated into mainstream curriculum.
Number of subjects: 0
Study 10954389 — intervention group
Group type: EXPERIMENTAL
Intervention: Linkage between school and broader community.
Number of subjects: 0
Study 8682157 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard 131I activity of 555 MBq
Number of subjects: 92
Study 8682157 — intervention group
Group type: COMPARATOR
Intervention: Calculated activity to deliver a thyroid dose of 100 Gy
Number of subjects: 92
Study 8682157 — intervention group
Group type: EXPERIMENTAL
Intervention: Radioiodine treatment
Number of subjects: 92
Study 1872664 — intervention group
Group type: EXPERIMENTAL
Intervention: Psyllium
Number of subjects: 163
Study 1872664 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylcellulose
Number of subjects: 163
Study 1872664 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium polycarbophil
Number of subjects: 163
Study 1872664 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 163
Study 6763202 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Number of subjects: 249
Study 6763202 — intervention group
Group type: EXPERIMENTAL
Intervention: Codeine 60 mg
Number of subjects: 249
Study 6763202 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 650 mg
Number of subjects: 249
Study 6763202 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 650 mg + Codeine 60 mg
Number of subjects: 249
Study 6763202 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg + Codeine 60 mg
Number of subjects: 249
Study 6763202 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 249
Study 30526364 — intervention group
Group type: EXPERIMENTAL
Intervention: webCBT
Number of subjects: 594
Study 28058962 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid (HA) injection
Number of subjects: 75
Study 28058962 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine (LI) injection
Number of subjects: 75
Study 25599309 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized walking programme (WP)
Number of subjects: 246
Study 25599309 — intervention group
Group type: EXPERIMENTAL
Intervention: Group exercise class (EC)
Number of subjects: 246
Study 25599309 — intervention group
Group type: COMPARATOR
Intervention: Usual physiotherapy (UP)
Number of subjects: 246
Study 23475164 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrate-rich concentrated beetroot juice (BR; 2 × 250 mL·d, ∼8.2 mmol·d nitrate)
Number of subjects: 9
Study 23475164 — intervention group
Group type: COMPARATOR
Intervention: Nitrate-depleted BR placebo (PL; 2 × 250 mL·d, ∼0.006 mmol·d nitrate)
Number of subjects: 9
Study 21969639 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 1460
Study 21969639 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 1460
Study 21969639 — intervention group
Group type: EXPERIMENTAL
Intervention: Perphenazine
Number of subjects: 1460
Study 21969639 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 1460
Study 21969639 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 1460
Study 19407730 — intervention group
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine (50-400 mg/day)
Number of subjects: 2950
Study 19407730 — intervention group
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine (50 mg/day)
Number of subjects: 2950
Study 19407730 — intervention group
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine (400 mg/day)
Number of subjects: 2950
Study 19407730 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2950
Study 19407730 — intervention group
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine
Number of subjects: 2950
Study 17217572 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg Ca/d
Number of subjects: 21
Study 17217572 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg Ca/d
Number of subjects: 21
Study 17217572 — intervention group
Group type: COMPARATOR
Intervention: 0 mg Ca/d
Number of subjects: 21
Study 15060225 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication algorithm-medication alone (MedMgt)
Number of subjects: 0
Study 15060225 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (Comb)
Number of subjects: 0
Study 15060225 — intervention group
Group type: COMPARATOR
Intervention: Behavior modification (Beh)
Number of subjects: 0
Study 15060225 — intervention group
Group type: COMPARATOR
Intervention: Community comparison (CC)
Number of subjects: 0
Study 15060225 — intervention group
Group type: EXPERIMENTAL
Intervention: Med/NoMed (stopping medication)
Number of subjects: 0
Study 15060225 — intervention group
Group type: EXPERIMENTAL
Intervention: Med/Med (consistent medication use)
Number of subjects: 0
Study 15060225 — intervention group
Group type: EXPERIMENTAL
Intervention: NoMed/Med (starting medication)
Number of subjects: 0
Study 15060225 — intervention group
Group type: EXPERIMENTAL
Intervention: NoMed/NoMed (never reported medication use)
Number of subjects: 0
Study 11180733 — intervention group
Group type: EXPERIMENTAL
Intervention: Olympic Games transportation strategy
Number of subjects: 4
Study 9676863 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous clonidine 2 microg kg(‐1)
Number of subjects: 20
Study 9676863 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 20
Study 7848364 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotrimoxazole preparations and placebo
Number of subjects: 16
Study 7848364 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamin preparations and placebo
Number of subjects: 16
Study 7848364 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain questionnaire
Number of subjects: 16
Study 3261612 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (active treatment)
Number of subjects: 59
Study 3261612 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (control)
Number of subjects: 59
Study 30980569 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based medicine practices in obstetrics
Number of subjects: 0
Study 28686675 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg added after each IFNβ injection for 4 weeks
Number of subjects: 45
Study 28686675 — intervention group
Group type: COMPARATOR
Intervention: Placebo added to the standard treatment for FLS for 4 weeks
Number of subjects: 45
Study 28686675 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine
Number of subjects: 45
Study 28686675 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 24962864 — intervention group
Group type: EXPERIMENTAL
Intervention: LSG with omentopexy
Number of subjects: 60
Study 24962864 — intervention group
Group type: COMPARATOR
Intervention: LSG without omentopexy (Control)
Number of subjects: 60
Study 23701059 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraparenchymal blood patch
Number of subjects: 242
Study 23701059 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraparenchymal blood patch with 19-gauge needle
Number of subjects: 242
Study 23701059 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraparenchymal blood patch with 17-gauge needle
Number of subjects: 242
Study 21591944 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium (100 μg twice daily)
Number of subjects: 159
Study 21591944 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (600 mg twice daily)
Number of subjects: 159
Study 21591944 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 159
Study 19246990 — intervention group
Group type: EXPERIMENTAL
Intervention: HCV Core ISCOMATRIX vaccine (5, 20, or 50 microg HCV Core protein with 120 mug ISCOMATRIX adjuvant)
Number of subjects: 30
Study 19246990 — intervention group
Group type: COMPARATOR
Intervention: Placebo vaccine
Number of subjects: 30
Study 16918863 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse case management (CM) intervention
Number of subjects: 243
Study 16918863 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC) condition
Number of subjects: 243
Study 15157947 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibromyalgia group
Number of subjects: 0
Study 15157947 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 15157947 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple regression analysis
Number of subjects: 0
Study 11768700 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular sugarless gum
Number of subjects: 40
Study 11768700 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicarbonate sugarless gum
Number of subjects: 40
Study 11768700 — intervention group
Group type: COMPARATOR
Intervention: Control (normal postcibal buffering effects)
Number of subjects: 40
Study 9013351 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-seropositive patients with abdominal tuberculosis
Number of subjects: 108
Study 9013351 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-seronegative patients with abdominal tuberculosis
Number of subjects: 108
Study 9013351 — intervention group
Group type: COMPARATOR
Intervention: Patients with pulmonary tuberculosis
Number of subjects: 108
Study 9013351 — intervention group
Group type: COMPARATOR
Intervention: Volunteer blood donors
Number of subjects: 108
Study 9013351 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with abdominal tuberculosis (both HIV-seropositive and HIV-seronegative)
Number of subjects: 108
Study 9013351 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-seropositive patients
Number of subjects: 108
Study 7886411 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignocaine 400 mg (40 ml of a 1% solution) instilled for 1 hour in Group A patients (n = 9)
Number of subjects: 11
Study 7886411 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignocaine instilled for 2 hours in Group B patients (n = 2)
Number of subjects: 11
Study 7886411 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical application of lignocaine
Number of subjects: 11
Study 3164163 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training program for the stomatognathic system (E groups)
Number of subjects: 60
Study 3164163 — intervention group
Group type: COMPARATOR
Intervention: Control group (C groups)
Number of subjects: 60